References 1. Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105: 1135–1143. 2. Libby P (2002) Inflammation in atherosclerosis. Nature 420: 868–874. 3. Galkina E, Ley K (2009) Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol 27: 165–197. 4. Hansson GK, Libby P (2006) The immune response in atherosclerosis: a double- edged sword. Nat Rev Immunol 6: 508–519. 5. Seimon T, Tabas I (2009) Mechanisms and consequences of macrophage apoptosis in atherosclerosis. J Lipid Res 50 Suppl: S382–387. 6. Kanters E, Pasparakis M, Gijbels MJ, Vergouwe MN, Partouns-Hendriks I, et al. (2003) Inhibition of NF-kappaB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice. J Clin Invest 112: 1176–1185. 7. Gareus R, Kotsaki E, Xanthoulea S, van der Made I, Gijbels MJ, et al. (2008) Endothelial cell-specific NF-kappaB inhibition protects mice from atherosclero- sis. Cell Metab 8: 372–383. 8. Seimon TA, Wang Y, Han S, Senokuchi T, Schrijvers DM, et al. (2009) Macrophage deficiency of p38alpha MAPK promotes apoptosis and plaque necrosis in advanced atherosclerotic lesions in mice. J Clin Invest 119: 886–898. 9. Ashwell JD (2006) The many paths to p38 mitogen-activated protein kinase activation in the immune system. Nat Rev Immunol 6: 532–540. 10. Kumar S, Boehm J, Lee JC (2003) p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2: 717–726. 11. Beardmore VA, Hinton HJ, Eftychi C, Apostolaki M, Armaka M, et al. (2005) Generation and characterization of p38beta (MAPK11) gene-targeted mice. Mol Cell Biol 25: 10454–10464. 12. Zhao M, Liu Y, Wang X, New L, Han J, et al. (2002) Activation of the p38 MAP kinase pathway is required for foam cell formation from macrophages exposed to oxidized LDL. Apmis 110: 458–468. 13. Lei ZB, Zhang Z, Jing Q, Qin YW, Pei G, et al. (2002) OxLDL upregulates CXCR2 expression in monocytes via scavenger receptors and activation of p38 mitogen-activated protein kinase. Cardiovasc Res 53: 524–532. 14. Denes L, Jednakovits A, Hargitai J, Penzes Z, Balla A, et al. (2002) Pharmacologically activated migration of aortic endothelial cells is mediated through p38 SAPK. Br J Pharmacol 136: 597–603. 15. McMullen ME, Bryant PW, Glembotski CC, Vincent PA, Pumiglia KM (2005) Activation of p38 has opposing effects on the proliferation and migration of endothelial cells. J Biol Chem 280: 20995–21003. 16. Borbiev T, Birukova A, Liu F, Nurmukhambetova S, Gerthoffer WT, et al. (2004) p38 MAP kinase-dependent regulation of endothelial cell permeability. Am J Physiol Lung Cell Mol Physiol 287: L911–918. 17. Gratton JP, Morales-Ruiz M, Kureishi Y, Fulton D, Walsh K, et al. (2001) Akt down-regulation of p38 signaling provides a novel mechanism of vascular endothelial growth factor-mediated cytoprotection in endothelial cells. J Biol Chem 276: 30359–30365. The Role of P38a MAPK in Atherosclerosis 18. Viemann D, Goebeler M, Schmid S, Klimmek K, Sorg C, et al. (2004) Transcriptional profiling of IKK2/NF-kappa B- and p38 MAP kinase- dependent gene expression in TNF-alpha-stimulated primary human endothelial cells. Blood 103: 3365–3373. 19. Smith SJ, Fenwick PS, Nicholson AG, Kirschenbaum F, Finney-Hayward TK, et al. (2006) Inhibitory effect of p38 mitogen-activated protein kinase inhibitors on cytokine release from human macrophages. Br J Pharmacol 149: 393–404. 20. Kim C, Sano Y, Todorova K, Carlson BA, Arpa L, et al. (2008) The kinase p38 alpha serves cell type-specific inflammatory functions in skin injury and coordinates pro- and anti-inflammatory gene expression. Nat Immunol 9: 1019–1027. 21. Nolden L, Edenhofer F, Haupt S, Koch P, Wunderlich FT, et al. (2006) Site- specific recombination in human embryonic stem cells induced by cell-permeant Cre recombinase. Nat Methods 3: 461–467. 22. Schieven GL (2005) The biology of p38 kinase: a central role in inflammation. Curr Top Med Chem 5: 921–928. 23. Forde A, Constien R, Grone HJ, Hammerling G, Arnold B (2002) Temporal Cre-mediated recombination exclusively in endothelial cells using Tie2 regulatory elements. Genesis 33: 191–197. 24. Kiermayer C, Conrad M, Schneider M, Schmidt J, Brielmeier M (2007) Optimization of spatiotemporal gene inactivation in mouse heart by oral application of tamoxifen citrate. Genesis 45: 11–16. 25. Clausen BE, Burkhardt C, Reith W, Renkawitz R, Forster I (1999) Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res 8: 265–277. 26. Westra J, Doornbos-van der Meer B, de Boer P, van Leeuwen MA, van Rijswijk MH, et al. (2004) Strong inhibition of TNF-alpha production and inhibition of IL-8 and COX-2 mRNA expression in monocyte-derived macrophages by RWJ 67657, a p38 mitogen-activated protein kinase (MAPK) inhibitor. Arthritis Res Ther 6: R384–392. 27. Cuenda A, Rousseau S (2007) p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 1773: 1358–1375. 28. Jagavelu K, Tietge UJ, Gaestel M, Drexler H, Schieffer B, et al. (2007) Systemic deficiency of the MAP kinase-activated protein kinase 2 reduces atherosclerosis in hypercholesterolemic mice. Circ Res 101: 1104–1112. 29. Heinrichsdorff J, Luedde T, Perdiguero E, Nebreda AR, Pasparakis M (2008) p38 alpha MAPK inhibits JNK activation and collaborates with IkappaB kinase 2 to prevent endotoxin-induced liver failure. EMBO Rep 9: 1048–1054. 30. Zhang SH, Reddick RL, Piedrahita JA, Maeda N (1992) Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258: 468–471. 31. Ricci R, Sumara G, Sumara I, Rozenberg I, Kurrer M, et al. (2004) Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis. Science 306: 1558–1561. PLoS ONE | www.plosone.org 12 June 2011 | Volume 6 | Issue 6 | e21055